Schaut mal rein...Es könnte sich lohnen - 500 Beiträge pro Seite

[Tornado 34]

STRONG BUY......

918064 Nur handelbar über AMILAND...PINK SHEETS


GOOD LUCK

Alle weiteren Infos müsst Ihr Euch leider selbest besorgen...


Keine Zeit

[Tornado 34]

Kleiner Tipp

Business of ISI Overview



On March 11, 2003, ISI entered into the Inventory Agreement with HEB pursuant to which ISI sold HEB all of its inventory related to ALFERON N Injection and granted HEB a three year license to sell ALFERON N Injection in the United States. In addition, on March 11, 2003 substantially all of ISI`s employees became employees of HEB. ISI also entered into the Asset Purchase Agreement pursuant to which ISI has agreed to sell its property, plant, furniture, equipment, all customer lists, computer files, data and software, books and records, manufacturing records and procedures, approval processes and approvals with and by the U.S. Food and Drug Administration and all other property, patents, trademarks, and rights of every kind and nature owned or held by ISI relating to natural alpha interferon, its production, manufacture and sale. Upon completion of the Asset Purchase Agreement, ISI will not be involved in the natural alpha interferon business and will not have a manufacturing and research facility. Therefore, ISI`s remaining assets will consist of cash, 586,056 shares of HEB Common Stock (consisting of 99,028 shares currently held by ISI and an additional 487,028 shares of HEB Common Stock to be received upon completion of the Asset Purchase Agreement), a royalty from HEB equal to 6% of sales of products containing natural alpha interferon, a note receivable and a warrant to purchase shares of Amphioxus Cell Technologies, Inc. ("ACT"). ISI does not intend to distribute the HEB Common Stock to the ISI shareholders and has entered into a non-binding Letter of Intent to acquire ACT.

ACT Letter of Intent

On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI. The ACT Preferred Stock will be convertible at the option of the holder at any time, and subject to mandatory conversion if, prior to the date which is two years after the merger, the sum of the proceeds received from (i) the sale of the assets of ISI at the date of merger, and (ii) common equity capital raised at a pre-money valuation in excess of $10 million, exceed $2.5 million.

Certain debt (the "ACT Debt") aggregating approximately $2.9 million that is currently owed to shareholders of ACT will continue as secured non-interest bearing debt of ISI. The ACT Debt will be non-interest bearing and repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment of 25% of the net after tax profits of ACT over $1 million on a cumulative basis. The ACT Debt shall be fully payable upon a change of control of ISI (excluding the transactions whereby the ACT stockholders convert the ACT Preferred Stock). In addition, the ACT Debt shall also be repaid to the extent of the net proceeds from the sale of any equity securities of ISI exceeding $8 million. In addition, certain additional debt aggregating approximately $200,000 owed to a shareholder of ACT will be repayable on the fifth anniversary of the date of the merger.

In addition, preferred stock (the "Junior Preferred Stock") held by a shareholder of ACT will continue as non-accruing preferred stock in the face amount of $2 million, senior in right of preference as to dividends and distributions in liquidation to the ACT Preferred Stock and common stock of ISI. The Junior Preferred Stock will be repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment from 25% of the net after tax profits of ISI available after payment of the ACT Debt. The Junior Preferred Stock will also be subject to reset upon the following conditions: the redemption value and liquidation preference of Junior Preferred Stock shall be increased if either the market capitalization of ISI or the amount to be paid by any third party for ISI values the common stock and any other equity securities or debt convertible into equity securities at (i) greater than $25 million, in which case the Junior Preferred Stock shall be increased to $2.75 million, or
(ii) greater than $35 million, in which case the Junior Preferred Stock shall be increased to $3.5 million (each a "Reset Event"). If not sooner redeemed and paid, the Junior Preferred Stock shall be fully redeemed and retired (subject only to the prior payment of the ACT Debt) at any time upon a change of control of the surviving company (excluding the transaction whereby the ACT stockholders convert their ACT Preferred Stock), or to the extent of the net proceeds from the sale of any equity securities of ISI exceeds $10.9 million.

In addition, on the merger date, three officers of ISI have agreed to grant ISI the option to terminate their employment agreements in exchange for (i) a one-year consulting agreement at the rate of $4,000 per month, (ii) common stock or options exercisable into approximately 1.25% of ISI and (iii) an amount by which 10% of the proceeds from the sale of certain assets of ISI exceed $200,000.

The Letter of Intent is non-binding and subject to the execution of definitive documents and due diligence. However, the parties have agreed to use good faith efforts to negotiate such agreements, and consummate the transaction as soon as reasonably practicable.

Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and Amphioxus have decided not to proceed with a potential transaction unless and until such situation is resolved in a manner that is acceptable to Amphioxus and ISI. In addition, as of the date hereof, neither Amphioxus nor ISI has completed its due diligence and ISI has not received the financial statements of Amphioxus. At such time, if any, that ISI and Amphioxus continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues.

For the reasons set forth above, ISI does not believe the potential transaction between ISI and Amphioxus is probable of completion at the present time. In addition, ISI believes that the failure to complete the asset sale would have a material adverse effect on the ISI stockholders because if the asset sale is not completed, ISI believes that it is likely that it will file for or be forced to resort to bankruptcy protection. In that event, ISI believes that it is extremely unlikely that ISI would be able to pay, or provide for the payment of, all of its liabilities and obligations, and therefore, the ISI Common Stock would have little or no value. See "Risk Factors - Risks Relating to ISI - Failure to Complete the Asset Sale Could Result in Bankruptcy." Unfortunately, because of ISI`s precarious financial situation, ISI believes that the ISI stockholders have but one reasonable choice - to vote in favor of the proposed asset sale to HEB. ISI believes that a vote against the asset sale would lead to the consequences set forth above and preclude the potential transaction with Amphioxus from proceeding . For that reason, ISI believes that the inclusion of financial information regarding Amphioxus would not be material to a stockholder`s voting decision with respect to the asset sale by ISI to HEB.

Relationships between ACT and ISI.

Ms. Margie Chassman owns 16,000,032 shares of ISI common stock representing approximately 42.9 % of the outstanding common stock of ISI. In addition, she has warrants to purchase an additional 16,666,667 shares of ISI common stock. Ms. Chassman also owns 16.65 % of the common stock of ACT. Neither Ms. Chassman nor any designee of Ms. Chassman is a member of the Board of Directors of ISI. Ms. Chassman has no contracts, arrangements, understandings or relationships with ISI with respect to the ISI common stock owned by her. Ms. Chassman has agreed to vote her shares of ISI common stock in the same proportion as the other ISI stockholders vote with respect to any transaction requiring stockholder approval between ACT and ISI.

Property

ISI owns two freestanding buildings comprising approximately 43,000 square feet that are located in New Brunswick, New Jersey. ISI uses the facilities for staff offices, manufacturing, quality control and research activities, and storage. ISI`s properties are subject to the Asset Purchase Agreement.

Legal Proceedings

In September 2003, the Company was sued in an action seeking foreclosure of the Company`s property due to non-payment of city property taxes, water and sewer charges aggregating approximately $225,000. The Company had until October 17, 2003 to answer the complaint. After such time, the plaintiff has the right to seek an order giving the Company 30 days to pay the unpaid taxes. As of the date hereof, no such order has been received by the Company. If the taxes remain unpaid after the date set by the court, the court may make the plaintiff the owner of the property. The property is subject to the sale of the Company`s assets to HEB. Under the terms of the Asset Purchase Agreement, if the Company`s tax obligations become due and payable, HEB has the option to (i) terminate the Asset Purchase Agreement or (ii) satisfy the tax obligations and proceed to closing after the other conditions of the Asset Purchase Agreement have been satisfied. On December 24, 2003, HEB advised the Company that it had purchased all of the Company`s outstanding tax obligations (resulting from unpaid city property taxes, sewer and water charges) and threatened to continue a foreclosure proceeding against the Company`s property if the Company does not move expeditiously to close the Asset Purchase Agreement. The Company has not decided what action it will take if HEB seeks to continue the foreclosure proceeding. However, any further litigation between the Company and HEB may have a material adverse effect on the Company and its stockholders because (i) the expenses of such litigation will drain the Company`s already limited assets,
(ii) in the event the market price of HEB common stock is adversely affected by such litigation, the value of the consideration to be received by the Company upon the closing (if any) of the Asset Purchase Agreement (the Company is to receive 487,028 shares of HEB common stock) would be reduced, and (iii) such litigation would reduce the likelihood of closing the Asset Purchase Agreement in the near future.. See Note 15 of Notes to Consolidated Condensed Financial Statements of ISI for the Quarter ended September 30, 2003 contained elsewhere herein.

On September 16, 2003, HEB filed and subsequently served and moved for expedited proceedings on a complaint filed in the Court Of Chancery of the State of Delaware, New Castle County, against ISI. The Complaint seeks specific performance, and declaratory and injunctive relief related to the Inventory and Asset Purchase Agreements with ISI. Specifically, HEB alleges that ISI has delayed its performance pursuant to the Inventory and Asset Purchase Agreement and, as a result, the Asset Purchase Agreement did not close within 180 days of the date of the execution of the agreements. Paragraph 7.7 of the Asset Purchase Agreement states that either party to the agreement may terminate the agreement if there is no closing within 180 days of the date of the agreement. HEB requested that the Court require ISI to specifically perform its obligations under the agreement or, in the alternative, that paragraph 7.7 of the agreement be eliminated or reformed to eliminate ISI`s ability to terminate pursuant to that paragraph. HEB also requested that ISI, as a result of its conduct, not be permitted to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 or due to the passage of time. At a hearing held on September 29, 2003, the Court set a trial of the case for January 6-7, 2004 which was postponed until March 4-5, 2004. The parties have agreed that neither party shall have the right to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 until the date which is at least two weeks following trial and only then, unless the Court has ruled, upon five days written notice to the other party. In response to HEB`s complaint, ISI has filed a motion to dismiss.

[Tornado 34]

Schreibt mir doch mal Eure Meinung....Bitte

[Tornado 34]

HEB 4,09 Interferon...1,5Mille Shares=

6Millionen USD cash

[Tornado 34]

[Tornado 34]

Achtung interferon kurz vor dem Ausbruch..........HIGH 0,05.........75K

[Tornado 34]

Ich werde mich nun aus dem Board zurückziehen da mir eh keiner Meinungen schreibt.
Nicht das ich nacher noch schuld bin wenn es nichts wird.........WENN ABER DOCH DANN GEHT DIE PARTY AB

Aktuell 0,04...High 0,05.....

es geht doch....


Grüsse ....melde mich wieder nach dem SHAREHOLDERMEETING

-mal sehen was der Kurs bis dahin macht.

Good Luck
Torni

[Tornado 34]

Achtung.........

Sorry ich kann es nicht lassen........117K

0,06 BBBBUUUMMMMMMMMMMMM

50%%%%%%%%%%%%

[Tornado 34]

Jetzt ist das Teil auf 0,055......+35%

Sagt mal sind da nur Käufer aus USA????

Egal...es fängt erst an

[Tornado 34]

Date - Open- High -Low -Last -Change - Volume % Change
02/11/04´-- 0.0350- 0.0600 -0.0350- 0.0550-- +0.0150 174450- +37.50%


Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Hold
20 - 50 Day MACD Oscillator Hold
20 Day Bollinger Bands Hold

Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 28150

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Hold
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 19348

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Hold
50 - 100 Day MACD Oscillator Hold

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 27317

Overall Average: 56% - Buy

Price- Support- Pivot- Point- Resistance

0.04- 0.03- 0.04- 0.05


Aktuell 0,055

[Tornado 34]

Das glaube ich gar nicht. Gestriger Anstieg um 37% mit einem absoluten Volumen von 180K auf 0,055
aber was mich wundert ist das sich keiner zu Wort meldet.
Hier ist echt Totenstille und ISI steigt.
Hat wohl keiner Interesse. Nun dann sei es so

Muss ich ja dann auch nichts mehr schreiben.

Also der nächste Anstieg folgt bestimmt. Ich bin der Meinung das es erst so richtig losgeht. Schaut Euch mal das vergangene Jahr an und betrachtet die grünen Striche was die Volumenkäufe betrifft
Also wenn ich das addiere erhalte ich zu 75% versteckte Käufe oder es ist alles nur Mmanipuliert. Was ich aber bei diesen Aussichten nicht glaube.

Gestern hatten wir in kürzester Zeit über 30 Trades bei 0,05 und 0,06 Da hat sich einer eingedeckt.

Also bis dann.....mal ne richtige Meinung wäre nicht schlecht.
Danke und Grüsse

Torni

[Tornado 34]

Scheiss Werbung....... Einen habe ich aber noch



IFSC - INTERFERON SCI (OTC)
Date Open High Low Last Change Volume % Change
02/11/04 0.04 0.06 0.04 0.05 +0.02 181600 +37.50%



Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest

Short Term Indicators
7 Day Average Directional Indicator Buy Average Strongest
10 - 8 Day Moving Average Hilo Channel Buy Average Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Hold Steady
20 Day Bollinger Bands Buy Maximum Strongest

Short Term Indicators Average: 80% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Strong Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Hold Steady
50 Day Parabolic Time/Price Buy Average Strongest

Medium Term Indicators Average: 75% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Hold Steady

Long Term Indicators Average: 67% - Buy

Overall Average: 80% - Buy

[Tornado 34]

Schaut Euch nur mal das Verhältnis rot -grün an
Das sind nun 7 Monate ....Wer hat da gekauft?????
Also einen kenne ich schon...Ich...

[Tornado 34]

Company News and Press Releases From Other Sources:

INTERFERON SCIENCES INC, (SC 13G/A) Statement of Ownership Filed By ALPHA CAPITAL AKTIENGESELLSCHAFT

--------------------------------------------------------------------------------


--------------------------------------------------------------------------------



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*



Interferon Sciences, Inc.

--------------------------------------------------------------------------------

(Name of Issuer)



COMMON STOCK, $.01 PAR VALUE

--------------------------------------------------------------------------------

(Title of Class of Securities)



458903408

--------------------------------------------------------------------------------

(CUSIP Number)


*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


(Continued on following page(s))


--------------------------------------------------------------------------------




Page 1 of 4 Pages



--------------------------------------------------------------------------------


----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Alpha Capital Aktiengesellschaft
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 6,221,089 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 6,221,089 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,221,089 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |X|

The aggregate amount in Row 9 represents the maximum amount of shares
that Alpha Capital can beneficially control under a contractually
stipulated 9.9% ownership restriction. The full exercise of Alpha
Capital`s Warrants would exceed this restriction.
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------






--------------------------------------------------------------------------------


CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---

ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.

ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:

783 Jersey Avenue, New Brunswick, NJ 08901

ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Aktiengesellschaft

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein

ITEM 2 (c) CITIZENSHIP: Liechtenstein

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value

ITEM 2 (e) CUSIP NUMBER: 458903408

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable

ITEM 4 OWNERSHIP

(a) AMOUNT BENEFICIALLY OWNED: 6,221,089 Shares of Common Stock

(b) PERCENT OF CLASS: 9.9%

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

6,221,089 Shares

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

6,221,089 Shares

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares






--------------------------------------------------------------------------------


CUSIP NO. 458903408 PAGE 4 OF 4 PAGES
--- ---


Strong buy

[Tornado 34]

[Tornado 34]

ES WIRD ZEIT DER ZUG ROLLT


@all es wird wieder Zeit sich zu Wort zu melden

Seit meinem ersten Posting das IFSC nach oben geht , hat sich bestättigt das etwas ganz grosses kommen wird

Ich hatte Euch bei 0,03 geraten einzusteigen....Nun sind wir bereits auf 0,06 und waren schon bei 0,07........

ISI steigt und steigt....Ich kann nur raten einzusteigen bevor der grosse run kommt.

Schaut Euch mal ganz genau den Chart an........und den der letzten Jahre...

Viel Erfolg und bis dann.

News gibt es auch schon wieder

[Tornado 34]

Da sich hier wohl keiner meldet ist auch kaum einer investiert....

Na dann AUFGEHTS........

[Tornado 34]

@all

da hier irgendwie kein Interesse besteht sich zu unterhalten werde ich mich nun -in the Underground- of Interferon begeben.

LINKS , NEWS, und die aktuelle Lage wisst Ihr ja nun zu genüge. Mir ist das irgendwie zu doof zu posten und nichts tut sich.

Wer will : per Postfach

Viel Glück ......

P.S Melde mich später dann wieder wenn ich reich bin

Und nicht vergessen Stichtag.......baaaaaallllddddd

[Tornado 34]

Der Stichtag war bereits

Respekt.........

IFSC News sind schon veröffentlicht und der Deal wurde wie von mir angekündigt, abgeschlossen. Könnte sich lohnen. Zumal steht IFSC erst bei 0,06 und hat viel Zukunftsmusik.....


Interferon Sciences Completes Sale of Assets to Hemispherx Biopharma

NEW BRUNSWICK, N.J., Mar 17, 2004 (BUSINESS WIRE) -- Interferon Sciences, Inc. (ISI) (IFSC - PINK SHEETS) announced today it had completed the sale to Hemispherx Biopharma, Inc. (HEB) of substantially all of its assets including, but not limited to, real estate, machinery and equipment and all of the rights to its natural alpha interferon business.
For these assets, ISI:

(i) received 424,528 shares of HEB Common Stock which has a Guaranteed Value (as defined in the Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without a Guaranteed Value; and

(iii) will receive a royalty equal to 6% of the net sales of any products containing natural alpha interferon sold by HEB (or a Marketing Partner, as defined in the Asset Sale Agreement).

In addition, HEB satisfied certain obligations relating to the real estate, machinery and equipment of ISI which aggregated approximately $ 2,500,000.

The Asset Sale Agreement obligates HEB to register the HEB Common Stock, sets periodic limits on the number of these shares that may be sold and requires HEB to pay ISI an amount equal to the product received by multiplying (i) the number of Guaranteed Shares remaining unsold on March 17, 2006 and (ii) $ 1.59.




Company News and Press Releases From Other Sources:

Hemispherx Biopharma Completes Acquisition for Worldwide Rights to Alferon N


Company Closes Final Agreement on GMP Certified Manufacturing Facility; Expects International Sales to Begin During the Second Quarter

PHILADELPHIA, Mar 18, 2004 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it has completed the second and final agreement with Interferon Sciences (ISI), including the acquisition of all the worldwide rights on Alferon N(R) as well as an FDA approved biological production facility of 44,000 square feet located in New Brunswick, New Jersey.
On March 11, 2003, Hemispherx Biopharma executed two agreements with Interferon Sciences to purchase certain assets of ISI and consummated the first agreement. In the first transaction, the Company acquired the inventory of Alferon N Injection(R) and a limited license for the production, manufacture, use, marketing and sale of the product.

In the second agreement, the Company acquired all intellectual, proprietary and commercial rights to Alferon N(R) and other assets related to the product including, but not limited to, all real estate and machinery.

"We are excited that we have successfully completed the transaction, which gives us complete ownership of the Alferon N(R) technology," said Dr. William A. Carter, Hemispherx`s CEO and President. "The closing of the agreement allows us to expand the Alferon N(R) Program, which consists of Alferon N Injection(R), Alferon N LDO(R) and Alferon N Gel(R), outside of the United States. We expect to start clinical trials and generate sales with Alferon N(R) internationally in the second quarter of this year."

About Alferon N(R)

Alferon N(R) (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of refractory papilloma infections (HPV) and is also approved for sale by various regulatory agencies worldwide.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.

SOURCE: Hemispherx Biopharma, Inc.



Die Rakete wird bald zünden oder hat schon

[weierHai]

Hallo Tornado,

wo bleiben deine Anschlußorders??
Schließlihc soll der Kurs doch nach oben gezogen werden, damit die Lemmige auf den Zug aufspringen!
derweiße Hai

[Tornado 34]

Es gibt keine Anschlussorders mehr

Und überhaupt....was soll das mit den Lemmingen. Wenn ich aufs Knöpchen drücke stehen wir bei 0,01.......Also verzapfe bitte nicht solchen.........Müll.

Bin heute schlecht gelaunt........grrrrrrrrrrrr.......

Habe irgendie keine Lust mehr hier zu posten da sowieso keiner eine wirkliche Meinung oder mal eine INFO rüberlässt.

Wir sehen uns..... Und Sorry nehme mir mein Verhalten nicht übel, doch ich finde es aber auch nicht gut von Lemmingen zu sprechen..bla bla bla....schliesslich sitzen wir imselben Boot und wer ne Ahnung hat der weis das IFSC weit aus mehr Wert ist...als dieser lächerliche Kurs.

Von mir gibts keine Infos mehr.....mir reichts

Bussi

[weierHai]

Hallo Tornado,

wollte Dich nicht ärgern!!!

Hatte gehofft auf diese Weise neue News zu erhalten. Ich weiß wir brauchen alleeinen langen Atem. Aber gestern stand wieder ein neuer Artikel unter HEB über 489 Seiten!

Der Schwerpunkt lag hier eindeutig auf dem Präparat von interferon. Man setzt hier große Stücke auf die Alferon Entwicklung.
Auch ich bin ein überzeugter IFS Aktionär, die Aktie wird ihren Weg machen.
Schließlich war sie gestern als Depotstütze ( da kein Umsatz) schon gut zu gebrauchen!!

also nichts für Ungut, werde mich zukünftig zügeln!!
Hoffe Du versorgst uns weiterhin mit News!!
bis dann
der weiße Hai